Mcl-1-IN-23 

Mcl-1-IN-23 is a Mcl-1 inhibitor with a K_i value of 0.024 μM. Mcl-1-IN-23 binds directly to Mcl-1 and displaces the pro-apoptotic proteins Bak and Bim from Mcl-1 complexes. Mcl-1-IN-23 induces cell apoptosis, activates caspase-3, promotes PARP cleavage, and exerts antiproliferative activity against cancer cells. Mcl-1-IN-23 can be used for the research of leukemia^[1].

Mcl-1-IN-23 (Compound 53) reversibly binds to purified Mcl-1 protein at a 1:1 ratio, with a K_d value of 0.31 μM, and the binding process is jointly mediated by enthalpy and entropy^[1].
Mcl-1-IN-23 serves as a long-acting ligand for purified GST-Mcl-1 protein, with a K_d value of 1.89 μM, and exhibits slow binding and dissociation kinetic processes^[1].
Mcl-1-IN-23 (48 h) potently inhibits the proliferation of Mcl-1-sensitive Molm-13 cells with an IC₅₀ of 0.45 μM; it remains active against Venetoclax (HY-15531)-resistant Molm-13_VenR cells with an IC₅₀ of 1.16 μM; and it exhibits low micromolar activity against other hematological tumor cell lines^[1].
Mcl-1-IN-23 (0-10 μM; 4 h) dose-dependently displaces the pro-apoptotic proteins Bim and Bak from Mcl-1 in Molm-13 cells, indicating that it can target and inhibit Mcl-1^[1].
Mcl-1-IN-23 (0.3-3 μM; 48 h) induces apoptosis in Molm-13 cells in a dose-dependent manner^[1].
Mcl-1-IN-23 (0-10 μM; 24 h) activates the apoptotic pathway in Molm-13 cells via concentration-dependent cleavage of PARP and Caspase-3, without affecting the expression levels of Bcl-2 or Bcl-xL, confirming that the apoptosis it induces is dependent on Mcl-1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mcl-1-IN-23 (Compound 53) (2-10 mg/kg; intravenous injection, oral administration; single dose) exhibits excellent in vivo pharmacokinetic properties in SD rats, including an oral bioavailability of 32%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

655.25

C₃₈H₃₉ClN₂O₄S

2756736-34-0

ClC1=C(C)C=C(OCCCN2C(C)=C(S(=NCC3=CC=C(C4=CC=CC=C4)C=C3)(C5=CC=C(C)C=C5)=O)C(C)=C2C(O)=O)C=C1C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang J, et al.. Development of highly selective, low-toxicity and orally available Mcl-1 inhibitors based on 3,5-dimethyl-4-sulfonimide-1H-pyrrole scaffold via P2/P3 dual pocket binding optimization. European journal of medicinal chemistry. 2026 May 29;316:119010.  [Content Brief]